Short answer
Lantheus Holdings, Inc. (LNTH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $390M (up 1.5% year over year) with net income of $22M.
Q3 2026 key financials · XBRL
- Revenue
- $390M
- +1.5% YoY · +0.4% QoQ
- Net income
- $22M
- −19.4% YoY · −70.2% QoQ
- Operating margin
- 8.3%
- Gross margin
- 62.4%
- EPS (diluted)
- $0.30
- −34.8% YoY · −73.0% QoQ
Source: XBRL data from the Lantheus Holdings, Inc. (LNTH) Q3 2026 10-Q on SEC EDGAR. USD.
Lantheus Holdings, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $389.9M, up 1.5% YoY from $384.0M
- Net income $22.4M, down 19.4% YoY from $27.8M
- Best segment Neurology: Neuraceq revenue $45.6M, up 123.0% YoY
- Operating margin 8.3% vs 11.4% YoY, calculated from reported operating income and revenue
- Cash $683.6M; nine-month operating cash flow $319.3M vs $300.0M, no 2026 share repurchases
- Near-term headwinds: PYLARIFY price decline, competition, LNTH-2501 CRL, Merger regulatory approvals pending
Risk Factors
- New merger risk: FTC Second Request on October 21, 2026 extended HSR review and could require divestitures or block closing
- Regulatory risk: LNTH-2501 FDA Complete Response Letter cited unresolved third-party manufacturing conditions
- Operational risk: PYLARIFY TruVu launch depends on PMF technology transfers, FDA approvals, and customer adoption beginning Q4 2026
- Financial risk: merger termination fee of $228.0 million could reduce cash available for general corporate purposes
- Asset risk: LNTH-2620 and LNTH-2515 impairment charges totaled $31.0 million after TAUKLARIFY approval changed development plans
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lantheus Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.